Category: Press Release

2022.03.29

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021

2022.03.18

I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022

2022.03.15

I-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act

2022.03.09

I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

2022.03.03

I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer

2022.01.28

I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs

2022.01.18

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors

2022.01.14

I-Mab Announces Execution of Senior Management Team Share Purchase Plan

2022.01.12

I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors

2022.01.06

I-Mab Announces Senior Management Team Share Purchase Plan